VEGFA and pulmonary fibrosis: Previous work has shown that AP-Cav, called cavtratin,5 has beneficial therapeutic effects in a variety of models, including pulmonary fibrosis,10 hypertension,11 hyperoxic lung damage,12 heart failure,13 sepsis,14,15 liver fibrosis,16 cancer,5 multiple sclerosis (MS),17 asthma,18 and ocular diseases, including ischemic and VEGF driven retinal degeneration.19